Asset Details
Do you wish to reserve the book?
Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Do you wish to request the book?
Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
2020
Overview
The terminal complement protein (C5) inhibitor eculizumab (Soliris
®
) is the first agent to be specifically approved in the EU, USA, Canada and Japan for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who are aquaporin-4 water channel autoantibody (AQP4-IgG) seropositive and (in the EU only) for those with a relapsing course of disease. In the phase III PREVENT trial, eculizumab significantly reduced the risk of adjudicated relapse relative to placebo in patients with AQP4-IgG-seropositive NMOSD, approximately a quarter of whom did not receive concomitant immunosuppressive therapies. The beneficial effect of eculizumab was seen across all patient subgroups analysed and was accompanied by improvements in neurological and functional disability assessments, as well as generic health-related quality of life measures; it was sustained through 4 years of treatment, according to combined data from the PREVENT trial and an interim analysis of its ongoing open-label extension study. The safety profile of eculizumab in AQP4-IgG-seropositive NMOSD was consistent with that seen for the drug in other approved indications. Thus, eculizumab provides an effective, generally well tolerated and approved treatment option for this rare, disabling and potentially life-threatening condition.
Video abstract
2qKwCupTrKm1nhKJcp11T2
Video Abstract (MP4 241640 KB)
Publisher
Springer International Publishing,Springer Nature B.V
Subject
/ Adults
/ Antibodies, Monoclonal, Humanized - pharmacology
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Complement C5 - antagonists & inhibitors
/ Complement Inactivating Agents - pharmacology
/ Complement Inactivating Agents - therapeutic use
/ Humans
/ Medicine
/ Neuromyelitis Optica - drug therapy
